MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock...
$38,896
Net cash provided by
financing activities
$38,896
Net (decrease)
increase in cash and cash...
-$483,062
Canceled cashflow
$38,896
Accounts payable and
accrued expenses
$328,005
Accrued compensation
$163,776
Prepaid expenses and
other assets
-$154,688
Non-cash interest
expense
$126,028
Stock-based compensation
expense
$105,056
Inventories
-$41,964
Non-cash operating lease
expense
$19,146
Net cash used in
operating activities
-$521,958
Canceled cashflow
$938,663
Net loss
-$1,156,208
Accounts receivable
$285,043
Operating lease
liabilities
-$19,370
Back
Back
Cash Flow
source: myfinsight.com
Evoke Pharma Inc (EVOK)
Evoke Pharma Inc (EVOK)